Abstract:The EGFR family play a significant role in cell signal transduction and their overexpression is implicated in the pathogenesis of numerous human solid cancers. Inhibition of the EGFR-mediated signaling pathways by EGFR inhibitors is a widely used strategy for the treatment of cancers. In most cases, the EGFR inhibitors used in clinic were only effective when the cancer cells harbored specific activating EGFR mutations which appeared to preserve the ligand-dependency of receptor activation but altered the pattern of downstream signaling pathways. Moreover, cancer is a kind of multifactorial disease, and therefore manipulating a single target may result in treatment failure. Although drug combinations for the treatment of cancers proved to be successful, the use of two or more drugs concurrently still was a challenge in clinical therapy owing to various dose-limiting toxicities and drug-drug interactions caused by pharmacokinetic profiles changed. Therefore, a single drug targeting two or multiple targets could serve as an effective strategy for the treatment of cancers. In recent, drugs with diverse pharmacological effects have been shown to be more advantageous than combination therapies due to their lower incidences of side effects and more resilient therapies. Accordingly, dual target-single-agent strategy has become a popular field for cancer treatment, and researchers became more and more interest in the development of novel dual-target drugs in recent years. In this review, we briefly introduce the EGFR family proteins and synergisms between EGFR and other anticancer targets, and summarizes the development of potential dual target inhibitors based on wild-type and/or mutant EGFR for the treatment of solid cancers in the past five years. Additionally, the rational design and SARs of these dual target agents are also presented in detailed, which will lay a significant foundation for the further development of novel EGFR-based dual inhibitors with excellent druggability.

Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies

Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment

Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present)

Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer

Present and Future Perspective on PLK1 Inhibition in Cancer Treatment

Plk1 As A Potential Drug Target in Cancer Therapy

Sequentially targeting and intervening mutual Polo-like Kinase 1 on CAFs and tumor cells by dual targeting nano-platform for cholangiocarcinoma treatment

Recent Advances in Multi-target Drugs Targeting Protein Kinases and Histone Deacetylases in Cancer Therapy

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)

Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects

Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors

Recent Progress in CDK4/6 Inhibitors and PROTACs

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

Structure-based discovery of 1-(3-fluoro-5-(5-(3-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)phenyl)-3-(pyrimidin-5-yl)urea as a potent and selective nanomolar type-II PLK4 inhibitor

Exploring Novel PLK1 Inhibitors Based on Computational Studies of 2,4-Diarylaminopyrimidine Derivatives

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

PLK1: a promising and previously unexplored target in double-hit lymphoma.

Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities

Recent researches for dual Aurora target inhibitors in antitumor field

Development of PI3K inhibitors: Advances in clinical trials and new strategies (Review)